XML 65 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Segment Reporting

In the periods set out below, U.S. and International Product sales by franchise were as follows:
 
Three months ended
 
September 30, 2018
 
September 30, 2017
(In millions)
U.S. Sales
 
International Sales
 
Total Sales
 
U.S. Sales
 
International Sales
 
Total Sales
Product sales by franchise
 
 
 
 
 
 
 
 
 
 
 
IMMUNOGLOBULIN THERAPIES
$
530.7

 
$
125.2

 
$
655.9

 
$
486.6

 
$
118.5

 
$
605.1

HEREDITARY ANGIOEDEMA
291.3

 
37.7

 
329.0

 
235.8

 
32.6

 
268.4

BIO THERAPEUTICS
91.9

 
120.4

 
212.3

 
86.3

 
110.3

 
196.6

Immunology
913.9

 
283.3

 
1,197.2

 
808.7

 
261.4

 
1,070.1

HEMOPHILIA
386.6

 
349.3

 
735.9

 
357.5

 
367.8

 
725.3

INHIBITOR THERAPIES
44.7

 
124.4

 
169.1

 
70.6

 
120.1

 
190.7

Hematology
431.3

 
473.7

 
905.0

 
428.1

 
487.9

 
916.0

VYVANSE
528.5

 
66.5

 
595.0

 
476.8

 
61.6

 
538.4

ADDERALL XR
71.5

 
4.8

 
76.3

 
99.4

 
6.6

 
106.0

MYDAYIS
19.3

 
—

 
19.3

 
10.2

 
—

 
10.2

Other Neuroscience(1)
0.9

 
40.2

 
41.1

 
6.7

 
29.8

 
36.5

Neuroscience
620.2

 
111.5

 
731.7

 
593.1

 
98.0

 
691.1

ELAPRASE
41.7

 
128.9

 
170.6

 
41.4

 
111.5

 
152.9

REPLAGAL
—

 
123.0

 
123.0

 
—

 
117.2

 
117.2

VPRIV
39.0

 
48.8

 
87.8

 
37.5

 
52.1

 
89.6

Genetic Diseases
80.7

 
300.7

 
381.4

 
78.9

 
280.8

 
359.7

LIALDA/MEZAVANT
88.9

 
30.2

 
119.1

 
61.4

 
25.3

 
86.7

PENTASA
65.7

 
—

 
65.7

 
72.1

 
—

 
72.1

Other Established Brands(2)
10.7

 
21.0

 
31.7

 
11.4

 
20.3

 
31.7

Established Brands
165.3

 
51.2

 
216.5

 
144.9

 
45.6

 
190.5

GATTEX/REVESTIVE
82.2

 
14.9

 
97.1

 
72.6

 
12.3

 
84.9

NATPARA/NATPAR
47.8

 
3.2

 
51.0

 
39.1

 
—

 
39.1

Other Internal Medicine(3)
0.1

 
28.9

 
29.0

 
0.6

 
35.9

 
36.5

Internal Medicine
130.1

 
47.0

 
177.1

 
112.3

 
48.2

 
160.5

Ophthalmics
92.1

 
1.3

 
93.4

 
77.4

 
—

 
77.4

Oncology (4)
33.4

 
17.1

 
50.5

 
47.2

 
21.3

 
68.5

Total product sales
$
2,467.0

 
$
1,285.8

 
$
3,752.8

 
$
2,290.6

 
$
1,243.2

 
$
3,533.8

(1) Other Neuroscience includes INTUNIV, EQUASYM, and BUCCOLAM.
(2) Other Established Brands includes FOSRENOL and CARBATROL.
(3) Other Internal Medicine includes AGRYLIN, PLENADREN, and RESOLOR.
(4) Results include the Oncology franchise until the date of its sale on August 31, 2018.

In the periods set out below, Royalties and other revenues were as follows:
 
Three months ended
(In millions)
September 30, 2018
 
September 30, 2017
Royalties
$
45.1

 
$
111.4

Other revenues
73.8

 
52.4

Royalties and other revenues
$
118.9

 
$
163.8


 
Nine months ended
 
September 30, 2018
 
September 30, 2017
(In millions)
U.S. Sales
 
International Sales
 
Total Sales
 
U.S. Sales
 
International Sales
 
Total Sales
Product sales by franchise
 
 
 
 
 
 
 
 
 
 
 
IMMUNOGLOBULIN THERAPIES
$
1,409.6

 
$
416.3

 
$
1,825.9

 
$
1,299.9

 
$
314.0

 
$
1,613.9

HEREDITARY ANGIOEDEMA
949.9

 
113.1

 
1,063.0

 
878.9

 
89.5

 
968.4

BIO THERAPEUTICS
254.8

 
328.9

 
583.7

 
231.9

 
314.8

 
546.7

Immunology
2,614.3

 
858.3

 
3,472.6

 
2,410.7

 
718.3

 
3,129.0

HEMOPHILIA
1,152.6

 
1,072.8

 
2,225.4

 
1,082.1

 
1,037.5

 
2,119.6

INHIBITOR THERAPIES
160.5

 
422.7

 
583.2

 
217.4

 
414.5

 
631.9

Hematology
1,313.1

 
1,495.5

 
2,808.6

 
1,299.5

 
1,452.0

 
2,751.5

VYVANSE
1,572.3

 
207.5

 
1,779.8

 
1,445.4

 
174.9

 
1,620.3

ADDERALL XR
219.4

 
12.7

 
232.1

 
225.9

 
16.4

 
242.3

MYDAYIS
40.4

 
—

 
40.4

 
25.9

 
—

 
25.9

Other Neuroscience(1)
6.0

 
111.8

 
117.8

 
13.5

 
77.8

 
91.3

Neuroscience
1,838.1

 
332.0

 
2,170.1

 
1,710.7

 
269.1

 
1,979.8

ELAPRASE
126.6

 
338.9

 
465.5

 
119.4

 
335.1

 
454.5

REPLAGAL
—

 
372.8

 
372.8

 
—

 
349.0

 
349.0

VPRIV
113.9

 
153.4

 
267.3

 
110.3

 
147.0

 
257.3

Genetic Diseases
240.5

 
865.1

 
1,105.6

 
229.7

 
831.1

 
1,060.8

LIALDA/MEZAVANT
194.8

 
92.2

 
287.0

 
402.0

 
67.6

 
469.6

PENTASA
215.6

 
—

 
215.6

 
224.5

 
—

 
224.5

Other Established Brands(2)
43.8

 
62.1

 
105.9

 
67.0

 
55.3

 
122.3

Established Brands
454.2

 
154.3

 
608.5

 
693.5

 
122.9

 
816.4

GATTEX/REVESTIVE
280.2

 
46.6

 
326.8

 
193.3

 
35.9

 
229.2

NATPARA/NATPAR
153.5

 
7.3

 
160.8

 
103.2

 
0.1

 
103.3

Other Internal Medicine(3)
0.8

 
100.5

 
101.3

 
1.3

 
103.9

 
105.2

Internal Medicine
434.5

 
154.4

 
588.9

 
297.8

 
139.9

 
437.7

Ophthalmics
252.9

 
2.9

 
255.8

 
173.4

 
—

 
173.4

Oncology (4)
124.8

 
63.6

 
188.4

 
135.3

 
54.0

 
189.3

Total product sales
$
7,272.4

 
$
3,926.1

 
$
11,198.5

 
$
6,950.6

 
$
3,587.3

 
$
10,537.9

(1) Other Neuroscience includes INTUNIV, EQUASYM, and BUCCOLAM.
(2) Other Established Brands includes FOSRENOL and CARBATROL.
(3) Other Internal Medicine includes AGRYLIN, PLENADREN, and RESOLOR.
(4) Results include the Oncology franchise until the date of its sale on August 31, 2018.

In the periods set out below, Royalties and other revenues were as follows:
 
Nine months ended
(In millions)
September 30, 2018
 
September 30, 2017
Royalties
$
175.4

 
$
329.7

Other revenues
183.0

 
148.1

Royalties and other revenues
$
358.4

 
$
477.8